Journal: Orthopedics and Sports Medicine: Open Access Journal
Published: February 15,2019 Volume: 2 Issue: 4
DOI: 10.32474/OSMOAJ.2019.02.000145 ISSN: 2638-6003
Authors: Mahendra Kumar Trivedi and Snehasis Jana
Citation: Mahendra Kumar T, Snehasis J. Assessment of Bone Health Biomarker (ALP) after Treatment with Biofield Energy Treated DMEM in MG-63 Cells. Orthop & Spo Med Op Acc J 2(4)- 2019. OSMOAJ.MS.ID.000145. DOI: 10.32474/OSMOAJ.2019.02.000145.
- 37 Views
- 3 Downloads
The aim was to examine the effect of Biofield Treated DMEM on bone health in MG-63 cells. Dulbecco’s Modified Eagle’s Medium was used as a test sample in this study and divided into two parts. First part received Biofield Treatment by Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while the second part received two-times Biofield Treatment and denoted as BT-II. MTT assay was studied for cell viability, which was found as more than 73.9% in MG-63 cell line, which indicated with a safe and non-toxic profile. The bone health parameter, the level of ALP was significantly (p≤0.001) increased by 42.86% in both BT-I and BT-II groups compared with the untreated DMEM group. Thus, the data suggested that the Biofield Treated DMEM significantly improved ALP level, which can be used for the management of osteoporosis, deformed bones, bone and/or joint pain, rickets, osteoma, osteomalacia, aging, hormonal imbalance, and stress.
Bone health study was conducted and the Biofield Treated DMEM was used to study the level of alkaline phosphatase (ALP) enzyme. MTT assay for cell viability was done and the data showed more than 73.9% viable cells in the tested groups, which suggest that the DMEM was safe and non-toxic. ALP, the bone health parameter was significantly (p≤0.001) increased by 42.86% in both one-time Biofield Energy Treated DMEM (BT-I) and two-times Biofield Treated DMEM groups as compared with the untreated DMEM group. The Biofield Treated DMEM was found to have a significant impact on bone ALP level. Thus, with respect to the untreated DMEM, the Biofield Treated DMEM would be highly significant in the growth of MG-63 cells. Therefore, Biofield Treated DMEM might be a suitable alternative media for cell growth, and for the management of certain disorders like rickets, osteoporosis, bone loss and fractures, Paget’s disease, deformed bones, osteoma, osteomalacia, stress, hormonal imbalance, aging. Additionally, it might be useful to improve various physiological process those are involved in the communication from one cell to another cells, cell cycling, growth, proliferation, differentiation, neurotransmission, cardiovascular functions, hormonal balance, and skin health. It can also use in organ transplants like kidney, heart, and liver transplants, hormonal imbalance, aging, and various immune-related disorders (ulcerative colitis, dermatitis, irritable bowel syndrome, Alzheimer’s disease, hashimoto thyroiditis, asthma, multiple sclerosis, pernicious anemia, sjogren syndrome, aplastic anemia, hepatitis, graves’ disease, myasthenia gravis, dermatomyositis, diverticulitis, diabetes, atherosclerosis, Parkinson’s disease, systemic lupus erythematosus, stress, etc.).